Lancet Public Health最新文献

{"title":"Correction to Lancet Public Health 2025; 10: e588–98","authors":"","doi":"10.1016/s2468-2667(25)00176-8","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00176-8","url":null,"abstract":"No Abstract","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"5 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis","authors":"Michiyo Iwami, Oumnia Bouaddi, Mohammad S Razai, Rania Mansour, Beatriz Morais, Nafeesa Mat Ali, Alison F Crawshaw, Sainabou Bojang, Farah Seedat, Anna Deal, Sophie Webb, Jessica Carter, Nathaniel Aspray, Nuria Sanchez Clemente, Juan Arroyo-Laguna, Sanjeev Krishna, Yolanda Augustin, Henry M Staines, Sally Hargreaves","doi":"10.1016/s2468-2667(25)00148-3","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00148-3","url":null,"abstract":"<h3>Background</h3>WHO's Cervical Cancer Elimination Initiative has set a target for 90% of girls to be fully vaccinated against human papillomavirus (HPV) by the age of 15 years by 2030, to substantially reduce deaths from cervical and other HPV-related cancers. However, progress has been slow, with only 27% global vaccine coverage in 2023. Migrants are an under-immunised group globally for many vaccine-preventable diseases, with data showing that they experience a high burden of HPV infection and widespread HPV under-immunisation. We aimed to identify drivers of HPV vaccine uptake in migrants, as well as assess uptake and explore recommended approaches, strategies, and best practices to promote uptake in migrant communities.<h3>Methods</h3>In this systematic review and meta-analysis, we searched seven databases and several grey literature sources for information published in any language between Jan 1, 2006, and Dec 4, 2024, on the drivers of HPV vaccine uptake among migrants globally. Defining migrants as foreign-born nationals, we included qualitative and quantitative cross-sectional studies, cohort studies, and randomised controlled trials focused on first-generation and second-generation migrants and excluded studies of internal migrants. Outcomes were frequency and percentage of HPV vaccine uptake; factors positively or negatively influencing uptake; and recommended approaches, strategies, and best practices to promote uptake as reported by study authors or participants. We conducted a hybrid thematic analysis using the WHO Behavioural and Social Drivers of Vaccination model to map drivers of uptake, and a random-effects meta-analysis to calculate pooled estimates of uptake. Risk of bias was assessed using Joanna Briggs Institute checklists. This study is registered with PROSPERO, CRD42022347513.<h3>Findings</h3>Of 3562 records returned by the search, 117 studies were included in the analysis, involving 5 638 838 participants across 16 countries and one territory, of whom 933 189 were first-generation and second-generation migrants. The pooled estimates of HPV vaccine uptake were 23·0% (95% CI 10·0–44·0; <em>I</em><sup>2</sup>=99·3%; n=7614) among female migrants, 21·0% (5·0–58·0; <em>I</em><sup>2</sup>=99·3%; n=2764) among male migrants, and 17·0% (8·0–33·0; <em>I</em><sup>2</sup>=98·0%; n=3583) among male and female migrants combined. 79 (68%) studies were considered at low risk of bias, 32 (27%) were considered at moderate risk, and six (5%) were considered at high risk. Factors negatively influencing vaccine uptake included concerns about vaccine safety, cultural beliefs, uncertainty and low levels of knowledge about HPV vaccines or infection, exposure to negative information, and lack of recommendations from health-care providers. Practical barriers to uptake included little information on services, language barriers, logistical challenges, and the high cost of the vaccine. Enablers mainly included positive perceptions and trust in th","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"14 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study","authors":"Bernardo Meza-Torres, Gavin Jamie, Rashmi Wimalaratna, Robert Williams, Rachel Byford, Anna Forbes, William Elson, William Hinton, Jose M Ordóñez-Mena, Marinos Pericleous, Michael Feher, Martin Whyte, Mark Joy, Simon de Lusignan","doi":"10.1016/s2468-2667(25)00139-2","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00139-2","url":null,"abstract":"<h3>Background</h3>International guidelines recommend the administration of two doses of pre-exposure hepatitis A vaccination for people with chronic liver disease to prevent severe complications. We aimed to describe hepatitis A vaccination coverage and mortality in adults with chronic liver disease in England.<h3>Methods</h3>We did a retrospective cohort study using routinely collected medical record data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC) primary care sentinel network. We included people aged 18 years or older who were diagnosed with chronic liver disease between Jan 1, 2012, and Dec 31, 2022. The primary outcome of interest was hepatitis A vaccination. Hepatitis A vaccination coverage was calculated using the number of vaccinated people with chronic liver disease as the numerator and the chronic liver disease population in the RSC dataset as the denominator. We compared individual characteristics by vaccination status using descriptive statistics. We used a multistate survival model to estimate the transition probabilities between four states: (1) diagnosis of chronic liver disease; (2) first hepatitis A vaccination; (3) second hepatitis A vaccination; and (4) death.<h3>Findings</h3>664 571 individuals aged 18 years or older with chronic liver disease were identified from the RSC sentinel network population, of whom 625 079 individuals were included in our analysis. Of 625 079 individuals with chronic liver disease, 13 875 (2·2%) had received a first hepatitis A vaccination, 3007 (0·4%) had received a second dose, 732 (5·3%) of 13 875 vaccinated individuals died, and 101 065 (16·5%) of 611 204 individuals without vaccination died during the study period. Adjusting for death as a competing risk, vaccination was more likely among younger age quintiles (hazard ratio 5·46 [95% CI 5·13–5·81]), non-smokers (1·59 [1·54–1·65]), residents of urban areas (1·28 [1·21–1·35]), individuals with higher socioeconomic status (1·06 [1·03–1·10]), and individuals with a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD; 1·71 [1·64–1·78]). Individuals with a history of harmful alcohol use (0·36 [0·32–0·39]), type 1 diabetes (0·46 [0·36–0·57]), chronic kidney disease (0·63 [0·57–0·70]), or mental disorders (0·66 [0·64–0·69]) were less likely to be vaccinated. The lowest risk of mortality was in people with chronic liver disease of infectious or autoimmune aetiology and in people with MASLD.<h3>Interpretation</h3>Hepatitis A vaccine uptake among people with chronic liver disease in England is low, with disparities by age, location (urban <em>vs</em> rural), and socioeconomic status. Steps should be taken to reduce the inequalities in vaccine administration.<h3>Funding</h3>GlaxoSmithKline's Investigator Sponsored Studies Program.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"131 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Public Health 2025; 10: e189–202","authors":"","doi":"10.1016/s2468-2667(25)00177-x","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00177-x","url":null,"abstract":"No Abstract","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"93 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The OurFutures Vaping eHealth intervention to prevent e-cigarette use among adolescent students in Australia: a cluster randomised controlled trial","authors":"Lauren A Gardner, Nicola C Newton, Amy-Leigh Rowe, Siobhan O’Dean, Maree Teesson, Leanne Hides, Nyanda McBride, Matthew Sunderland, Becky Freeman, Lyra Egan, Annabelle Hawkins, Rhiannon Ellem, Amra Catakovic, Elise Caradmone, Chloe Alcorn, Kathleen Blackburn, Jazlyn East, Louise Thornton, Lexine Stapinski, Louise Birrell, Emily Stockings","doi":"10.1016/s2468-2667(25)00145-8","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00145-8","url":null,"abstract":"<h3>Background</h3>E-cigarette use among adolescents is a global public health concern. The efficacy of scalable prevention approaches is yet to be established. We aimed to evaluate the efficacy of a school-based eHealth intervention (OurFutures Vaping) to prevent e-cigarette use among adolescents.<h3>Methods</h3>A two-arm cluster randomised controlled trial was conducted among year 7 and 8 students (12–14 years) in 40 secondary schools across three Australian states: New South Wales, Western Australia, and Queensland. Schools were randomly assigned (1:1) to OurFutures Vaping (a four-lesson, web-based skills and education programme) or an active control group (usual health education) by a biostatistician using the Blockrand function in R, stratified by state and school gender composition. All year 7 and 8 students who attended participating schools, were fluent in English, and provided consent were eligible to participate. Teachers, students, and researchers were not masked to allocation. The primary outcome was past 12-month e-cigarette use, assessed at the 12-month follow-up. Intention-to-treat analyses were conducted using generalised mixed effects regression, with random effects accounting for participants clustered within schools. The trial was prospectively registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12623000022662).<h3>Findings</h3>Between January and October, 2023, we recruited 49 schools (7653 students). Nine schools withdrew before baseline (three control; six intervention). A total of 40 schools with 5157 eligible students (2329 [46·0%] girls and 2600 [51·3%] boys; mean age 13·30 years [SD 0·60]) completed the baseline survey in the intervention (20 schools, 2449 students) and control (20 schools, 2708 students) groups. Compared with the control group, participants who received the intervention had reduced odds of past 12-month e-cigarette use (odds ratio 0·35 [95% CI 0·18–0·66], p=0·0013) 1 year after receiving the intervention, indicating a 65% reduction in the odds of use among students who received the intervention compared with the control. No adverse events were reported.<h3>Interpretation</h3>The OurFutures Vaping programme offers an efficacious demand-reduction approach to prevent e-cigarette use among adolescents.<h3>Funding</h3>The Medical Research Future Fund and the Australian National Health and Medical Research Council.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"69 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening salt reduction strategies in the out-of-home food sector: warning labels and beyond","authors":"Elisa Pineda","doi":"10.1016/s2468-2667(25)00168-9","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00168-9","url":null,"abstract":"High dietary salt intake is a major contributor to elevated blood pressure and cardiovascular disease globally.<span><span>¹</span></span> Although the link between excessive sodium intake and health risks is well established, implementing effective policies to reduce population-level salt consumption remains a crucial public health challenge. In the UK and many other countries, much of the salt consumed originates from processed and out-of-home foods, for which regulatory oversight is often weaker than it is for packaged products.<span><span>2</span></span>, <span><span>3</span></span> Addressing sodium content in this sector is a pressing need.<span><span>⁴</span></span>","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"13 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis A targeted vaccination in England: a system challenge","authors":"Sema Mandal, David Leeman, Mary E Ramsay","doi":"10.1016/s2468-2667(25)00149-5","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00149-5","url":null,"abstract":"Most sporadic cases of hepatitis A diagnosed in England are associated with travel to endemic countries. Occasional outbreaks result from person-to-person transmission following initial importations<span><span>²</span></span> or contaminated food.<span><span>3</span></span>, <span><span>4</span></span> Since hepatitis A incidence in the UK is low, hepatitis A immunisation is only recommended for people at high risk of exposure (including travellers to endemic countries, people who inject drugs, and men who have sex with men) and for those at increased risk of complications, such as people with chronic liver disease,<span><span>⁵</span></span> in whom infection might lead to acute fulminant hepatitis and potentially death.<span><span>⁶</span></span>","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"15 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salt warning labels in the out-of-home food sector: online and real-world randomised controlled trials in the UK","authors":"Rebecca Evans, Jane Brealey, Natasha Clarke, Jennifer Falbe, Amy Finlay, Andrew Jones, Paula Thorp, Beth Witham, Rozemarijn Witkam, Eric Robinson","doi":"10.1016/s2468-2667(25)00143-4","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00143-4","url":null,"abstract":"<h3>Background</h3>High salt intake increases the risk of cardiovascular disease. The salt content of many commonly consumed foods in the out-of-home food sector (eg, restaurants) is excessive, but there are few policy options to address this problem. In this study, we evaluated an emerging policy approach—high salt warning labels on packaged food and resturant menus—for which, to date, there is little supporting evidence from randomised controlled trials.<h3>Methods</h3>These randomised controlled trials (one online study and one trial conducted in a real-world setting) were conducted in the UK. For study 1, an online study, participants (stratified by age, sex, and education to be representative of the UK adult population) were eligible if they were a current UK resident, aged 18 years or older, fluent in English, purchased supermarket sandwiches and savoury snacks, and ate out at or ordered from restaurants at least monthly. Exclusion criteria included being pregnant or breastfeeding or having major dietary restrictions. Participants were randomly assigned (1:1:1:1:1) to one of four different salt warning label conditions or to a control condition (QR code). Participants assigned to each group completed three packaged food scenarios and three restaurant ordering scenarios, all online, followed by questionnaires about the labelling and their food choices. The primary outcome was the perceived message effectiveness of salt warning labels. In study 2, the inclusion criteria were similar, except that participants who ate an out-of-home meal at least once a month were recruited. Exclusion criteria were severe dietary allergies and veganism. As in study 1, participants were stratified by age, sex, and education. Participants were randomly assigned (block randomisation with block size ~50) to receive menus with or without salt warning labels, from which they purchased and consumed lunchtime meals in a real-world restaurant. Participants then completed questionnaires. Primary outcomes were perceived message effectiveness and salt awareness. In both studies, perceived message effectiveness was measured with adapted versions of the University of North Carolina Perceived Message Effectiveness Scale. Participants in both studies were paid and masked to the study aims. Study 2 is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT06458270</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is complete.<h3>Findings</h3>In study 1, 2549 participants were randomly assigned to one of four salt warning label groups (red triangle, n=512; black triangle, n=512; red octagon, n=509; ","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"11 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis","authors":"Ding Ding, Binh Nguyen, Tracy Nau, Mengyun Luo, Borja del Pozo Cruz, Paddy C Dempsey, Zachary Munn, Barbara J Jefferis, Cathie Sherrington, Elizabeth A Calleja, Kar Hau Chong, Rochelle Davis, Monique E Francois, Anne Tiedemann, Stuart J H Biddle, Anthony Okely, Adrian Bauman, Ulf Ekelund, Philip Clare, Katherine Owen","doi":"10.1016/s2468-2667(25)00164-1","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00164-1","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Despite the rapid increase in evidence from the past decade on daily steps and health-related outcomes, existing systematic reviews primarily focused on few outcomes, such as all-cause mortality. This study synthesised the prospective dose-response relationship between daily steps and health outcomes including all-cause mortality, cardiovascular disease, cancer, type 2 diabetes, cognitive outcomes, mental health outcomes, physical function, and falls.&lt;h3&gt;Methods&lt;/h3&gt;For this systematic review and meta-analysis, we searched PubMed and EBSCO CINAHL for literature published between Jan 1, 2014, and Feb 14, 2025, supplemented by other search strategies. Eligible prospective studies examined the relationship between device-measured daily steps and health outcomes among adults without restrictions on language or publication type. Pairs of reviewers (BN, KO, ML, and TN) independently did the study selection, data extraction, and risk of bias assessment using the 9-point Newcastle-Ottawa Scale. Hazard ratios (HRs) from individual studies were synthesised using random-effects dose-response meta-analysis where possible. Certainty of evidence was assessed using GRADE. This trial is registered with PROSPERO (CRD42024529706).&lt;h3&gt;Findings&lt;/h3&gt;57 studies from 35 cohorts were included in the systematic review and 31 studies from 24 cohorts were included in meta-analyses. For all-cause mortality, cardiovascular disease incidence, dementia, and falls, an inverse non-linear dose-response association was found, with inflection points at around 5000–7000 steps per day. An inverse linear association was found for cardiovascular disease mortality, cancer incidence, cancer mortality, type 2 diabetes incidence, and depressive symptoms. Based on our meta-analyses, compared with 2000 steps per day, 7000 steps per day was associated with a 47% lower risk of all-cause mortality (HR 0·53 [95% CI 0·46–0·60]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=36·3; 14 studies), a 25% lower risk of cardiovascular disease incidence (HR 0·75 [0·67–0·85]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=38·3%; six studies), a 47% lower risk of cardiovascular disease mortality (HR 0·53 [0·37–0·77]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=78·2%; three studies), a non-significant 6% lower risk of cancer incidence (HR 0·94 [0·87–1·01]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=73·7%; two studies), a 37% lower risk of cancer mortality (HR 0·63 [0·55–0·72]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=64·5%; three studies), a 14% lower risk of type 2 diabetes (HR 0·86 [0·74–0·99]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=48·5%; four studies), a 38% lower risk of dementia (HR 0·62 [0·53–0·73]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=0%; two studies), a 22% lower risk of depressive symptoms (HR 0·78 [0·73–0·83]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=36·2%; three studies), and a 28% lower risk of falls (HR 0·72 [0·65–0·81]; &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;=47·5%; four studies). Studies on physical function (not based on meta-analysis) reported similar inverse associations. The evidence certainty was moderate for all outcomes except for card","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"23 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social health—the neglected third pillar","authors":"","doi":"10.1016/s2468-2667(25)00175-6","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00175-6","url":null,"abstract":"On June 30, 2025, the WHO Commission on Social Connection published its flagship <span><span>report</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> <em>From loneliness to social connection—charting a path to healthier societies</em>, bringing attention to a timely and critical, but under-recognised public health issue. The report follows the 2023 <span><span>call from the US Surgeon General</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> Vivek Murthy (co-chair of the WHO Commission report) who declared loneliness and social isolation an epidemic in the USA, and the adoption by <span><span>the World Health Assembly</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> in May 2025, of the first resolution on social connection. The Commission on Social Connection report is unambiguous: social disconnection—social isolation or loneliness—is widespread, with severe effects on health, wellbeing, and society, and must be recognised and addressed accordingly. Yet, social isolation and loneliness have remained largely overlooked in public health agendas.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"8 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}